186 related articles for article (PubMed ID: 32448602)
1. Pathophysiology of blood-brain barrier in brain tumor. Novel therapeutic advances using nanomedicine.
Sharma HS; Muresanu DF; Castellani RJ; Nozari A; Lafuente JV; Tian ZR; Sahib S; Bryukhovetskiy I; Bryukhovetskiy A; Buzoianu AD; Patnaik R; Wiklund L; Sharma A
Int Rev Neurobiol; 2020; 151():1-66. PubMed ID: 32448602
[TBL] [Abstract][Full Text] [Related]
2. Multi-ligand functionalized blood-to-tumor sequential targeting strategies in the field of glioblastoma nanomedicine.
Martins C; Sarmento B
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1893. PubMed ID: 37186374
[TBL] [Abstract][Full Text] [Related]
3. Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme.
Jena L; McErlean E; McCarthy H
Drug Deliv Transl Res; 2020 Apr; 10(2):304-318. PubMed ID: 31728942
[TBL] [Abstract][Full Text] [Related]
4. Molecular Mechanisms of Drug Resistance in Glioblastoma.
Dymova MA; Kuligina EV; Richter VA
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203727
[TBL] [Abstract][Full Text] [Related]
5. Nanocarrier-based drug combination therapy for glioblastoma.
Zhao M; van Straten D; Broekman MLD; Préat V; Schiffelers RM
Theranostics; 2020; 10(3):1355-1372. PubMed ID: 31938069
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticles Mediated the Diagnosis and Therapy of Glioblastoma: Bypass or Cross the Blood-Brain Barrier.
Song X; Qian H; Yu Y
Small; 2023 Nov; 19(45):e2302613. PubMed ID: 37415556
[TBL] [Abstract][Full Text] [Related]
7. Brain-targeted Nano-architectures for Efficient Drug Delivery and Sensitization in Glioblastoma.
Ravuluri JAV; Rao V; Kumar G; Manandhar S; Cheruku SP; Bisht P; Chamallmudi MR; Nandakumar K; Kumar L; Kumar N
Curr Pharm Des; 2023; 29(22):1775-1790. PubMed ID: 37403389
[TBL] [Abstract][Full Text] [Related]
8. Strategies to Improve Drug Delivery Across the Blood-Brain Barrier for Glioblastoma.
Narsinh KH; Perez E; Haddad AF; Young JS; Savastano L; Villanueva-Meyer JE; Winkler E; de Groot J
Curr Neurol Neurosci Rep; 2024 May; 24(5):123-139. PubMed ID: 38578405
[TBL] [Abstract][Full Text] [Related]
9. Nanomedicine facilitated cell signaling blockade: difficulties and strategies to overcome glioblastoma.
Habeeb M; Vengateswaran HT; You HW; Saddhono K; Aher KB; Bhavar GB
J Mater Chem B; 2024 Feb; 12(7):1677-1705. PubMed ID: 38288615
[TBL] [Abstract][Full Text] [Related]
10. Overcoming delivery barriers in immunotherapy for glioblastoma.
Rui Y; Green JJ
Drug Deliv Transl Res; 2021 Dec; 11(6):2302-2316. PubMed ID: 34053034
[TBL] [Abstract][Full Text] [Related]
11. A receptor-mediated landscape of druggable and targeted nanomaterials for gliomas.
Di Filippo LD; de Carvalho SG; Duarte JL; Luiz MT; Paes Dutra JA; de Paula GA; Chorilli M; Conde J
Mater Today Bio; 2023 Jun; 20():100671. PubMed ID: 37273792
[TBL] [Abstract][Full Text] [Related]
12. Strategies to overcome/penetrate the BBB for systemic nanoparticle delivery to the brain/brain tumor.
Liu HJ; Xu P
Adv Drug Deliv Rev; 2022 Dec; 191():114619. PubMed ID: 36372301
[TBL] [Abstract][Full Text] [Related]
13. Covalent nano delivery systems for selective imaging and treatment of brain tumors.
Ljubimova JY; Sun T; Mashouf L; Ljubimov AV; Israel LL; Ljubimov VA; Falahatian V; Holler E
Adv Drug Deliv Rev; 2017 Apr; 113():177-200. PubMed ID: 28606739
[TBL] [Abstract][Full Text] [Related]
14. Reactive oxidative species (ROS)-based nanomedicine for BBB crossing and glioma treatment: current status and future directions.
Wu D; Chen X; Zhou S; Li B
Front Immunol; 2023; 14():1241791. PubMed ID: 37731484
[TBL] [Abstract][Full Text] [Related]
15. Adjusting the Molecular Clock: The Importance of Circadian Rhythms in the Development of Glioblastomas and Its Intervention as a Therapeutic Strategy.
Wagner PM; Prucca CG; Caputto BL; Guido ME
Int J Mol Sci; 2021 Aug; 22(15):. PubMed ID: 34361055
[TBL] [Abstract][Full Text] [Related]
16. Theranostics in Neurooncology: Heading Toward New Horizons.
Tolboom N; Verger A; Albert NL; Fraioli F; Guedj E; Traub-Weidinger T; Morbelli S; Herrmann K; Zucchetta P; Plasschaert SLA; Yakushev I; Weller M; Glas M; Preusser M; Cecchin D; Barthel H; Van Weehaeghe D
J Nucl Med; 2024 Feb; 65(2):167-173. PubMed ID: 38071569
[TBL] [Abstract][Full Text] [Related]
17. Nanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment.
Tang L; Feng Y; Gao S; Mu Q; Liu C
Front Pharmacol; 2021; 12():786700. PubMed ID: 34899350
[TBL] [Abstract][Full Text] [Related]
18. Recent advancements and theranostics strategies in glioblastoma therapy.
Baddam SR; Kalagara S; Kuna K; Enaganti S
Biomed Mater; 2023 Aug; 18(5):. PubMed ID: 37582381
[TBL] [Abstract][Full Text] [Related]
19. Theranostic Nanomedicine for Malignant Gliomas.
d'Angelo M; Castelli V; Benedetti E; Antonosante A; Catanesi M; Dominguez-Benot R; Pitari G; Ippoliti R; Cimini A
Front Bioeng Biotechnol; 2019; 7():325. PubMed ID: 31799246
[TBL] [Abstract][Full Text] [Related]
20. Nano-Therapies for Glioblastoma Treatment.
Alphandéry E
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31963825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
